home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

3.360 -0.090 (-2.61%)

Streaming Delayed Price Updated: 2:25 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Lantern Pharma Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stocks That Hit 52-Week Lows On Thursday ↗

October 27, 2022

On Thursday, 111 stocks hit new 52-week lows.

Via Benzinga

Lantern Pharma Touts Encouraging Positive Efficacy For Pancreatic Cancer Candidate ↗

September 14, 2022

Via Benzinga

Recap: Lantern Pharma Q2 Earnings ↗

August 08, 2022

Lantern Pharma (NASDAQ:LTRN) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For March 10, 2022 ↗

March 10, 2022

Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares...

Via Benzinga

Lantern Pharma to Present New Preclinical Data at Three Upcoming Scientific Conferences

October 25, 2022

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET

October 21, 2022

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio for Cancer Drug Candidate LP-300

October 20, 2022

From Lantern Pharma Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 12, 2022

Gainers Adamis Pharmaceuticals (NASDAQ:ADMP) shares moved upwards by 28.1% to $0.19 during Wednesday's pre-market session. The market value of their outstanding shares is at $28.1 million.

Via Benzinga

Lantern Pharma to Present at The MicroCap Rodeo Presents The Windy City Roundup 2022 on Wednesday, October 12 at 11:00 a.m. ET

October 11, 2022

Via ACCESSWIRE

Lantern Pharma to Present at Upcoming Investor Conferences

October 05, 2022

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual Meeting

September 23, 2022

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma to Host Virtual KOL Webinar on the Treatment of Pediatric Cancers During Childhood Cancer Awareness Month, featuring Peter Houghton, Ph.D.

September 19, 2022

From Lantern Pharma Inc.

Via Business Wire

Treating Pediatric Cancer? How Lantern Pharma Hopes To Improve The Lives Of Pediatric Cancer Patients During Childhood Cancer Awareness Month ↗

September 15, 2022

Every September organizations have worked to raise awareness for childhood cancer by participating in childhood cancer awareness month.

Via Benzinga

Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic Cancer at the AACR Special Conference for Pancreatic Cancer

September 14, 2022

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma CEO & President, Panna Sharma, to Speak at H.C. Wainwright’s 24th Annual Global Investment Conference in September 2022

August 30, 2022

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

August 19, 2022

Via ACCESSWIRE

Lantern Pharma Reports Second Quarter 2022 Financial Results and Operational Highlights

August 08, 2022

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma to Report Second Quarter 2022 Operating & Financial Results on August 8th, 2022 at 4:30 p.m. ET

August 01, 2022

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma's New Phase 2 Clinical Trial –Harmonic™ — Approved for Launch by the FDA ↗

July 19, 2022

When most people think of lung cancer, they often picture a smoker.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 15, 2022

Via Benzinga

Lantern Pharma Gets FDA Clearance for Mid-Stage Lung Cancer Study ↗

July 14, 2022

The Food and Drug Administration (FDA) has announced clearance to Lantern Pharma (NASDAQ: LTRN) to proceed with Phase 2 clinical trial of its investigational new drug LP-300 in combination with...

Via Benzinga

The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures ↗

July 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic™, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer

July 14, 2022

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma Management to Speak at Multiple Investor and Scientific Conferences in May 2022

May 05, 2022

From Lantern Pharma Inc.

Via Business Wire

Recap: Lantern Pharma Q1 Earnings ↗

May 03, 2022

Lantern Pharma (NASDAQ:LTRN) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Lantern Pharma missed estimated...

Via Benzinga

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗

May 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Lantern Pharma Earnings Preview ↗

May 02, 2022

Lantern Pharma (NASDAQ:LTRN) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Lantern...

Via Benzinga

Lantern Pharma Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

April 14, 2022

ORLANDO, FL / ACCESSWIRE / April 14, 2022 / RedChip Companies, Inc. today announced that Lantern Pharma (NASDAQ:LTRN),a clinical stage biopharmaceutical company using its proprietary RADR® artificial...

From RedChip

Via AccessWire

Topics Artificial Intelligence

Lantern Pharma: Q4 Earnings Insights ↗

March 10, 2022

Lantern Pharma (NASDAQ:LTRN) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Earnings Outlook For Lantern Pharma ↗

March 09, 2022

Lantern Pharma (NASDAQ:LTRN) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com